Table 5.
Association between metformin plus sodium-glucose transporter 2 inhibitors and metformin plus insulin and study outcomes before propensity score matching
| Outcomes | Treatment groups | ||
|---|---|---|---|
| Metformin + SGLT-2i (n = 67) | Other GLD (n = 583) | p value | |
| In-hospital deaths | 13 (19.4%) | 228 (39.1%) | 0.003 |
| ICU admission, mechanical ventilation, or in-hospital death | 35 (52.2%) | 375 (64.3%) | 0.051 |
| In-hospital complications | 33 (49.3%) | 351 (60.2%) | 0.132 |
| Long-time hospital stay | 8 (11.9%) | 130 (22.3%) | 0.087 |
| Metformin + insulin (n = 110) | Other GLD (n = 1375) | p value | |
| In-hospital deaths | 43 (39.1%) | 445 (32.4%) | 0.175 |
| ICU admission, mechanical ventilation, or in-hospital death | 76 (69.1%) | 810 (58.9%) | 0.084 |
| In-hospital complications | 73 (66.4%) | 756 (55.0%) | 0.030 |
| Long-time hospital stay | 21 (19.1%) | 320 (23.3%) | 0.360 |
Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
GLD glucose-lowering drugs, ICU intensive care unit, SGLT-2i sodium-glucose transporter 2 inhibitors